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differ between groups. In patients receiving second generation DES, more multivessel
PCI were performed (p=0.01). The overall incidence of PMI was 4.75%. Between first
and second generation DES, there was no significant difference in PMI (5.5% vs.4.0%;
p=0.29). In a multivariate analysis, only the total number of stents implanted (p<0.001)
and presentation with acute coronary syndrome (p=0.02) were independent predictors
of PMI.
Table 1. Cardiac biomarkers for each DES type and DES generation. Values are
mean±SD, numbers of patients (percentage). 
CK = creatine kinase; DES = drug-eluting stents.
Conclusion: Using the revised ARC definition of PMI, there was no significant
difference in PMI between first and second generation DES following routine clinical
PCI.
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Background: Stent underexpansion (SUE), defined by minimal stent CSA (MSA < 5
mm2), is the one of the most important predictor of in-stent restenosis (ISR) in the era
of drug-eluting stent (DES) implantation. However, the difference of predictors for
occurrence of ISR between SUE and non-SUE might not be well known.
Methods: The EXCELLENT and POET were a multicenter, randomized trial
comparing paclitaxel-eluting stent (PES) (n=121), sirolimus-eluting stent (SES),
zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) in patients with
stable or unstable angina. Angiographically ISR at follow-up was observed in 450
lesions treated with DES implantation. A total 393 of enrolled patients who underwent
post-intervention and 9-month follow-up IVUS investigation were followed clinically
for 3-year period (PES n=121, SES n=161, ZES n=59, EES n=52). We classified these
into 2 groups based on the MSA; SUE group (n=107, MSA < 5 mm2) vs. non-SUE
group (n=286, MSA ≥ 5 mm2).
Results: Significant intimal hyperplasia (IH) was defined as IH area more than 50%
area of stent. Overall, 25 lesions (23.3%) among SUE group had IVUS-defined ISR,
whereas 30 lesions (10.4 %) among non-SUE group has IVUS-defined ISR (p=0.005).
Multivariate logistic regression for the determinant for the IVUS-defined ISR in the
each groups were compared. In SUE group, diabetes mellitus [odd ratio (OR) =3.03,
confidence interval (CI) =1.10-8.39, p=0.0014] and long stent (> 28mm) (OR = 3.9,
CI = 1.2-12.6, p=0.017) were predictors for IVUS-defined ISR, however in non-SUE
group, diabetes mellitus (OR = 2.99, CI = 1.29-6.92, p=0.014) and age (OR = 1.24, CI
= 1.02-2.56, p=0.017) were predictors for IVUS-defined ISR at follow-up.
Conclusion: The difference of predictors for occurrence of ISR at follow-up might
exist between SUE and non-SUE group. However, in general, diabetes mellitus showed
a universal predictor for occurrence of ISR at follow-up regardless of under-expansion
after DES implantation.
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Background: Previous studies have demonstrated similar outcomes over the short to
mid-term in patients treated with paclitaxel-eluting stents (PESs) or sirolimus-eluting
stents (SESs). However there is limited ‘real-world’ data investigating long term
outcomes. This study compared outcomes at 5 years following revascularisation in the
two patient groups.
Methods: 4252 consecutive patients underwent PCI with either paclitaxel-eluting
(PES) or sirolimus-eluting stents (SES) at a single centre (October 2003 – January
2011). Indications for PCI included stable and unstable angina. Left main and vein
graft lesions were excluded. Demographic and procedural data were collected at the
time of intervention. All-cause mortality data were obtained from the Office of National
Statistics via the BCIS/CCAD national audit out to a median of 4.0 years (CI 2.4 – 5.6
years). Primary end point was major adverse cardiac events (MACE), a composite of
all-cause mortality, myocardial infarction and target vessel revascularization (TVR).
Results: There were 1592 (37%) patients treated with SES and 2,660 (63%) patients
treated with PES. Baseline demographic, angiographic, and procedural characteristics
were similar between the two groups. At 5 years there were no statistical differences
in MACE between the stent types (SES 15.9% 95% CI 12.7-19.4 vs. PES: 16.5% 95%
CI 12.6-20.3, p=0.9). This consisted of similar rates of all-cause mortality (10.1% vs.
9.3%, p=0.4), TVR (5.3% vs. 6.4%, p=0.4), and stent thrombosis (2% vs. 1.8%, p=0.5).
In diabetic patients (n=1172 (28%)), there was a trend towards lower MACE favouring
PES but this did not reach statistical significance (19% vs. 24%, p=0.16).
Conclusion: This observational analysis of PES and SES-treated patients demonstrates
similar overall safety and efficacy over a 5-year follow-up period with low rates of
TVR.
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